Michael R. McDonnell

October 9, 2026

Merit Medical Systems sets Q3 2026 earnings date. Merit Medical Systems announced it will report its third-quarter 2026 results on October 29, 2026. This upcoming earnings date is the primary catalyst for the stock, as investors await fresh financial updates. The company is currently trading within its 52-week range, with an average analyst target price of $101.45.

October 4, 2026

Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.

October 17, 2026

Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.